360
Participants
Start Date
January 14, 2025
Primary Completion Date
January 31, 2028
Study Completion Date
October 31, 2031
IMA203
one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
nivolumab plus relatlimab
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
lifileucel
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
nivolumab
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
pembrolizumab
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
ipilimumab
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Dacarbazine
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
temozolomide
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
paclitaxel
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
paclitaxel plus carboplatin
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
Albumin-Bound Paclitaxel
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
RECRUITING
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Charite Universitaetsmedizin Berlin KöR, Berlin
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
University of Pennsylvania, Abramson Cancer Center, Philadelphia
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
University Medical Center Hamburg-Eppendorf, Hamburg
RECRUITING
University of MD Greenebaum Comprehensive Cancer Center, Baltimore
RECRUITING
Virginia Commonwealth University, Richmond
RECRUITING
UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
University of Miami - Sylvester Comprehensive Cancer Cente, Miami
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Ohio State University, Columbus
RECRUITING
Cleveland Clinic, Taussig Cancer Institute, Cleveland
RECRUITING
Universitaetsklinikum Essen AöR, Essen
ACTIVE_NOT_RECRUITING
University Hospital Cologne AöR, Cologne
ACTIVE_NOT_RECRUITING
Universitaetsklinikum Bonn AöR, Bonn
RECRUITING
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Mainz
RECRUITING
Avera Cancer Institute, Sioux Falls
RECRUITING
Goethe University Frankfurt, Frankfurt am Main
RECRUITING
University of Nebraska Medical Center, Omaha
RECRUITING
Universitaetsklinikum Heidelberg AöR, Heidelberg
RECRUITING
Baylor University, Dallas
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Huntsman Cancer Institute, University of Utah, Salt Lake City
RECRUITING
Honor Health Research Institute, Scottsdale
RECRUITING
UCLA Hematology/Oncology, Los Angeles
RECRUITING
City of Hope National Medical Center, Duarte
RECRUITING
Universitaetsklinikum Erlangen AöR, Erlangen
RECRUITING
Stanford Cancer Center, Stanford
RECRUITING
Providence Cancer Institute Franz Clinic, Portland
ACTIVE_NOT_RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Yale Cancer Center, New Haven
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Technische Universitaet Dresden, Dresden
ACTIVE_NOT_RECRUITING
Universitaet Leipzig, Leipzig
Immatics US, Inc.
INDUSTRY